Hemab Therapeutics Holdings, Inc.
COAG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002114044
No open-market purchases or sales by Hemab Therapeutics Holdings, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $1.33B in total; Soros Fund Management is the only superinvestor holding it.
Superinvestors holding COAG, Q2 2026
1 superinvestor reports holding Hemab Therapeutics Holdings, Inc. on Form 13F, worth $918.3K in total. Weight is Hemab Therapeutics Holdings, Inc.'s share of each 13F portfolio; actions compare shares with Q1 2026.
| Superinvestor | % of portfolio | Shares | Value | vs. previous quarter |
|---|---|---|---|---|
| Soros Fund ManagementGeorge Soros | <0.1% | 25,000 | $918.3K | New |
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of COAG each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2026
1 superinvestor holding at quarter end